Celgene Sues Barr Over Generic Thalomid
Celgene Corp. has filed another patent suit against Barr Pharmaceuticals Inc. in an attempt to stave off generic competition for its lucrative cancer treatment Thalomid, which brought in $117.7 million in...To view the full article, register now.
Already a subscriber? Click here to view full article